M3 Valuation
Is 4YC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Share Price vs Fair Value
What is the Fair Price of 4YC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4YC?
Other financial metrics that can be useful for relative valuation.
| What is 4YC's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | JP¥1.02t |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.7x |
| Enterprise Value/EBITDA | 12.1x |
| PEG Ratio | 2.2x |
Price to Earnings Ratio vs Peers
How does 4YC's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 25.4x | ||
COP CompuGroup Medical SE KGaA | 25.4x | 26.1% | €1.3b |
NXU Nexus | 39x | 15.5% | €972.0m |
AFX Carl Zeiss Meditec | 28.9x | 12.7% | €7.5b |
M3V MeVis Medical Solutions | 8.4x | n/a | €48.4m |
4YC M3 | 22.5x | 10.4% | €1.0t |
Price to Earnings Ratio vs Industry
How does 4YC's PE Ratio compare vs other companies in the European Healthcare Services Industry?
Price to Earnings Ratio vs Fair Ratio
What is 4YC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 22.5x |
| Fair PE Ratio | 30.5x |
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?